Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations in LUX-Lung 3, a phase III trial of afatinib or cisplatin/pemetrexed in EGFR mutation-positive lung cancer

Abstract: 2123
Congress: ESMO 2012
Type: Abstract
Topic: NSCLC, metastatic
Authors: J. Yang1, M. Schuler2, N. Yamamoto3, K.J. O'Byrne4, V. Hirsh5, D. Massey6, T.S.K. Mok7, V. Zazulina6, M. Shahidi6, L.V. Sequist8; 1Taipei/TW, 2Essen/DE, 3Shizuoka/JP, 4Dublin/IE, 5Montreal, QC/CA, 6Bracknell/GB, 7Hong Kong/CN, 8Boston, MA/US